Addex Therapeutics Ltd (ADXN.SW) WACC Analysis

As of May 23, 2025, Addex Therapeutics Ltd (ADXN.SW) carries a Weighted Average Cost of Capital (WACC) of 5.2%. WACC reflects the blended rate Addex Therapeutics Ltd must pay to both equity and debt holders.

Within that, the cost of equity is 4.4%, the cost of debt is 7.0%, and the effective tax rate is 16.8%.

Breakdown of WACC Components

• Long-term bond rate: 1.0% – 1.5%
• Equity market risk premium: 5.1% – 6.1%
• Adjusted beta: 0.37 – 0.4
• Additional risk adjustment: 1.5% – 2.0%
• Debt-to-equity ratio: 0.05

What It Means for Investors

With a selected WACC of 5.2%, Addex Therapeutics Ltd must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects an attractive low cost of capital.